Raymond James last night initiated coverage of Milestone Pharmaceuticals (MIST) with a Strong Buy rating and $6 price target At current share levels, the market is only assigning less than $100M in peak sales for Cardamyst in paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm says this equates to just a 2% penetration into the 2M patient population. Raymond James believes Cardamyst “has all the fundamentals for a successful launch.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James
- Milestone Pharmaceuticals announces availability of Cardamyst on Express Scripts
- Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals
- Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target
- Midday Fly By: FedEx reports ‘beat and raise,’ Ecolab to acquire CoolIT